The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.
Also called NCT06030843
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 200 participants
- Sponsor
- Chulalongkorn University
- Registry
-
NCT06030843
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Thailand
- Registry status
- Recruiting
Technical summary
Registry record NCT06030843. Randomized; quadruple masking; primary purpose treatment. Start 2025-03-01 (actual); primary completion 2026-11-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
- Acronym
- TREAT-CRS
- Condition
- Empagliflozin in Cardiorenal Syndrome Type 1
- Intervention (Drug)
- Empagliflozin 10 MG
- Intervention (Drug)
- Placebo
- Lead sponsor
- Chulalongkorn University
Record details
- Record id
cardio:ct-nct06030843- Content hash
baaeda5d12051dc0319bca60b09ea6ff5f75727a3f5ef56d5b169b86a6b0ed5c